OMER

MKT CAP:$959M

Omeros Corporation

Market Cap

$959M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$13.52-$2.86 (-17.46%)

Apr 23, 2026

Company Details

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related ...

CEO

Gregory A. Demopulos

IPO Date

Oct 8, 2009

Website

www.omeros.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$1M

EPS (Diluted)

-$0.02

Free Cash Flow

-$109M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

FY 2025

Mar 31, 2026

$0EPS -$0.05

Q4 2025

Mar 31, 2026

$0EPS $1.42

Q3 2025

Nov 13, 2025

$0EPS -$0.47

Q2 2025

Aug 14, 2025

$0EPS -$0.43

FY 2024

Mar 31, 2025

$0EPS -$2.70

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 19	$30M	$30M	-$11M
Q4 19	$33M	$33M	-$24M
Q1 20	$24M	$23M	-$24M
Q2 20	$14M	$13M	-$28M
Q3 20	$26M	$26M	-$25M
Q2 21	$0	-$400.0K	-$46M
Q3 21	$0	-$300.0K	-$40M
Q4 21	-$80M	-$79M	-$101M
Q1 23	$0	$0	-$36M
Q2 23	$0	$0	-$41M
Q1 24	$0	-$204.0K	-$39M
Q3 24	$0	$0	-$35M
Q4 24	$0	-$301.0K	-$36M
Q2 25	$0	-$10M	-$32M
Q3 25	$0	$0	-$26M
Q4 25	$0	$0	-$29M

Valuation

Quarter	P/S	P/E
Q3 19	8.2x	—
Q4 19	6.6x	—
Q1 20	5.5x	—
Q2 20	7.9x	—
Q3 20	6.0x	—
Q2 21	15.2x	—
Q3 21	22.9x	—
Q4 21	—	2.3x
Q1 23	—	1.5x
Q2 23	—	1.8x
Q1 24	—	1.2x
Q3 24	—	—
Q4 24	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 19	-$8M	-$8M
Q4 19	-$23M	-$23M
Q1 20	-$9M	-$9M
Q2 20	-$38M	-$38M
Q3 20	-$35M	-$35M
Q2 21	-$28M	-$28M
Q3 21	-$24M	-$24M
Q4 21	-$18M	-$18M
Q1 23	$175M	$175M
Q2 23	-$32M	-$33M
Q1 24	-$42M	-$42M
Q3 24	-$32M	-$32M
Q4 24	-$29M	-$29M
Q2 25	-$22M	-$22M
Q3 25	-$18M	-$18M
Q4 25	-$40M	-$40M

Capital Expenditures

Quarter	CapEx
Q3 19	$39.0K
Q4 19	$16.0K
Q1 20	$66.0K
Q2 20	$144.0K
Q3 20	$73.0K
Q2 21	$88.0K
Q3 21	$103.0K
Q4 21	$74.0K
Q1 23	$0
Q2 23	$275.0K
Q1 24	$58.0K
Q3 24	$1.0K
Q4 24	$26.0K
Q2 25	$13.0K
Q3 25	$11.0K
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 19	+547.9%	+2.3%
Q4 19	+51.8%	+41.1%
Q1 20	+8.1%	+15.1%
Q2 20	-49.4%	+14.2%
Q3 20	-12.5%	+25.8%
Q2 21	-100.0%	-20.2%
Q3 21	-100.0%	-15.6%
Q4 21	-690.5%	-49.4%
Q1 23	-100.0%	-30.7%
Q2 23	—	-10.3%
Q1 24	—	-2.0%
Q3 24	+100.0%	+69.8%
Q4 24	—	-0.1%
Q2 25	—	-20.9%
Q3 25	—	-32.4%
Q4 25	—	-17.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 19	$3M	11.7%
Q4 19	$3M	9.9%
Q1 20	$3M	14.8%
Q2 20	$0	0.0%
Q3 20	$0	0.0%
Q2 21	$3M	—
Q3 21	$6M	—
Q4 21	$6M	—
Q1 23	$3M	—
Q2 23	$3M	—
Q1 24	$3M	—
Q3 24	$3M	—
Q4 24	$2M	—
Q2 25	$2M	—
Q3 25	$2M	—
Q4 25	$2M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q3 19	$24M	$17M	—
Q4 19	$41M	$16M	—
Q1 20	$29M	$18M	—
Q2 20	$24M	$17M	—
Q3 20	$31M	$20M	—
Q2 21	$30M	—	$15M
Q3 21	$26M	—	$14M
Q4 21	$27M	—	—
Q1 23	$25M	$11M	—
Q2 23	$30M	$11M	—
Q1 24	$27M	$12M	—
Q3 24	$24M	$11M	—
Q4 24	$23M	—	$12M
Q2 25	$22M	—	—
Q3 25	$16M	—	$10M
Q4 25	$19M	$10M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$9M	$133M	$142M
Q2 22	$14M	$108M	$123M
Q3 22	$146M	$75M	$221M
Q4 22	$11M	$184M	$195M
Q1 23	$4M	$368M	$371M
Q2 23	$7M	$335M	$341M
Q3 23	$31M	$280M	$310M
Q4 23	$7M	$165M	$172M
Q1 24	$2M	$229M	$230M
Q2 24	$2M	$157M	$159M
Q3 24	$2M	$122M	$123M
Q4 24	$3M	$87M	$90M
Q1 25	$4M	$48M	$52M
Q2 25	$2M	$27M	$29M
Q3 25	$2M	$34M	$36M
Q4 25	$10M	$162M	$172M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 19	49M	+0.6%	+1.5%
Q4 19	51M	+2.5%	+3.3%
Q1 20	54M	+7.3%	+10.8%
Q2 20	55M	+0.4%	+11.1%
Q3 20	58M	+6.8%	+17.9%
Q2 21	62M	+7.1%	+23.2%
Q3 21	63M	+0.2%	+15.1%
Q4 21	63M	+0.1%	+14.7%
Q1 23	63M	+0.4%	+7.9%
Q2 23	63M	+0.0%	+0.7%
Q1 24	59M	-6.4%	-5.9%
Q3 24	58M	-1.5%	-7.4%
Q4 24	58M	+0.4%	-7.4%
Q2 25	59M	+0.7%	-6.8%
Q3 25	66M	+13.1%	+12.7%
Q4 25	64M	-4.2%	+9.6%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 19	$126.5K	236
Q4 19	$522.1K	64
Q1 20	$367.8K	64
Q2 20	$211.4K	64
Q3 20	$408.0K	64
Q2 21	$0	63
Q3 21	$0	63
Q4 21	-$375.1K	213
Q1 23	$0	196
Q2 23	$0	196
Q1 24	$0	198
Q3 24	$0	198
Q4 24	$0	202
Q2 25	$0	202
Q3 25	$0	202
Q4 25	$0	175

Revenue / Employee